Regeneron Pharmaceuticals, Inc.

Genvec, Inc.

Sanofi Biotechnology

Bayer Healthcare LLC

Karen W Chu

Kristine A Erickson

Alyson J Berliner

Daniel B Dix

Kenneth S Graham

Stanley J Wiegand

Jingtai Cao

Ivan Borisovich Lobov

Paul D Kessler

Robert L Vitti

Saurabh Wadhwa

Ronald Buggage

Henrik S Rasmussen

Rafael Varona

Dominique Mery-Mignard

Valérie Corp Dit Genti

Preethi Aavali Sridhara Sundaram

Kay D Rittenhouse

Friedrich Asmus

Thomas Eissing

The present invention provides methods for treating or preventing diabetic retinopathy, e.g., nonproliferative diabetic retinopathy, by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of a 2 mg aflibercept by intravitreal injection q8 weeks after three or five initial monthly doses (2q8) or 2 mg q16 weeks after three initial monthly doses and one 8-week interval (2q16). Moreover, the present invention provides methods for reversing or halting the progression NPDR to PDR (e.g., such that the DRSS is reduced by 2 or 3 levels) or preventing the occurrence or reoccurrence of a vision threatening complication by administering aflibercept according to the dosing regimens set forth herein.

Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy

The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).

Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab

Use of a VEGF antagonist to treat angiogenic eye disorders

The present invention provides compositions and methods of treating and improving the symptoms of uveitis and/or macular edema using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).

Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same

The invention provides a method for treating a tumor in a human comprising administering to the tumor a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-&#x3b1; operably linked to a promoter, wherein the dose comprises about 1&#xd7;10to about 4&#xd7;10particle units (pu) of replication-deficient adenoviral vector, at least once in a therapeutic period comprising up to 10 weeks, whereby the tumor in human is treated.

Therapeutic regimen for treating cancer comprising the administration of adenoviral vectors comprising a TNF-&#x3b1; transgene

Growing community of inventors

White Plains, NY, United States of America

Karen W Chu